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ABSTRACT 
Objective: Tinidazole, a nitroimidazole derivative is having low aqueous solubility which is a major barrier for systemic drug absorption. The aim of 
the present research was to develop gastro retentive raft forming tablets of tinidazole to achieve prolonged gastric residence time and thus higher 
bioavailability.  
Methods: Solid dispersion of tinidazole was prepared by kneading method by using methanol and polyvinylpyrrolidone (PVP). Different 
concentration of sodium alginate and hydroxypropyl methylcellulose (HPMC) was used to formulate a suitable raft forming tablets and then 
evaluated for drug content, floating lag time, raft strength, raft volume, raft weight, drug release and release kinetics.  
Results: Fourier transform infra-red (FT-IR) study confirms compatibility between drug and polymer. The floating lag time was found in the range 
of 40±4 to 60±5 s for all the formulation. Raft strength for all the formulations was within the range from 3.03±0.12 to 5.92±0.06 g. The raft volume 
for all the formulation was found within the range of 7.37±1.86 to 9.84±2.76 ml. Raft weight was measured after completion of raft formation for 
each formulation and was found in the range of 5.21±1.17 to 7.88±1.95 g. In vitro dissolution was carried up to 8 h and percentage of drug release 
was found to vary between 79.71±2.18 to 94.32±1.79 %.  
Conclusion: It can be concluded that the combination of solid dispersion and raft formation increases the bioavailability of tinidazole in tablet 
formulation. 
Keywords: Tinidazole, Raft, Sodium alginate, HPMC, Solid dispersion 
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
DOI: http://dx.doi.org/10.22159/ijap.2017v9i1.15757 
 
INTRODUCTION 
Oral administration is the most convenient route for any drug delivery 
to the systemic circulation with high patient compliance and flexibility 
in formulation [1, 2]. The conventional oral dosage form shows limited 
bioavailability due to fast gastric emptying [3, 4]. Gastro retentive drug 
delivery systems are the systems which are retained in the stomach 
for a longer period of time and thereby improve the bioavailability of 
drugs [5]. If the drugs are poorly soluble in the intestine due to alkaline 
pH, gastric retention may increase solubility before they are emptied, 
resulting in gastrointestinal absorption of drugs with narrow 
therapeutic absorption window, as well as controlling the release of a 
drug having site specific absorption limitation [6].  
Raft-forming systems [7] have a carbonate components and upon 
reaction with gastric acid, bubbles form in gel, enabling the floating 
[8, 9]. The floating behaviour of the raft is obtained by the buoyancy 
and low density created by carbon dioxide formation. The 
mechanism involves the formation of cohesive gel in contact with 
gas fluids wherein each portion of liquid swells forming a 
continuous layer called raft. The system contains a gel forming agent 
(e. g. alginic acid) and sodium bicarbonate which forms a foaming 
sodium alginate gel (raft) when in contact with gastric fluids [10]. In 
the presence of gastric acid, the bicarbonate is converted to carbon 
dioxide which becomes entrapped within the gel precipitate, 
converting it into foam which floats on the surface of the gastric 
contents, much like a raft on water [8, 11]. 
Tinidazole, a derivative of 2-methylimidazole chemically known as 
1-[2-(ethyl sulphonyl) ethyl]-2-methyl-5-nitroimidazole is a 
systemic anti-protozoal agent [12]. Tinidazole is widely used for the 
treatment of trichomoniasis, giardiasis [13] and paediatric patients 
older than three years of age and for the treatment of intestinal 
amebiasis and amebic liver abscess caused by E. histolytica. Being a 
class II drug, tinidazole is having low aqueous solubility which is a 
major barrier for systemic drug absorption [14]. Among all the 
solubility enhancement method, solid dispersion is the most popular 
and simple method [15, 16]. For the dissolution rate limited system, 
solid dispersion technique is used widely. Use of different polymers 
and sugars and numerous techniques of solid dispersion have made 
this method a useful tool for enhancing bioavailability [17]. 
Therefore, an attempt has been made in the present research to 
study the efficacy of solid dispersed tinidazole in raft forming 
tablets. 
MATERIALS AND METHODS 
Materials 
Tinidazole was obtained as a gift sample from Sanroz Lifescience, 
Ahmedabad, India. Sodium alginate and sodium bicarbonate was 
commercially purchased from SD fine chemicals, Mumbai. HPMC was 
obtained as a gift sample from Alembic Ltd, Vadodara. PVP was 
procured from Nice Chemicals Pvt. Ltd, Kochi. All the chemicals used 
were of analytical grade. 
Methods 
Compatibility study using FT-IR 
Fourier transform infra-red (FTIR) spectroscopy has been used to 
study the physical and chemical interactions between drugs and 
excipients. FT-IR spectra were recorded with FT-IR (ATR) 
spectrophotometer (Bruker Alpha E). Each sample grounded and 
mixed with potassium bromide (KBr) (Uvasol, Merck, and KgaA, 
Germany). Pellets were prepared by using a hydraulic press with a 
pressure of 100 Kg/cm2 for 15 min. The pellets were then scanned 
from 4000 to 400 cm-1 with a mirror speed of 2 mm/s. Drug-
excipient compatibility study was carried out by FT-IR analysis of 
pure tinidazole, sodium alginate, HPMC, PVP, a solid dispersion of 
tinidazole, and a formulation containing tinidazole. 
Formulation of solid dispersion of tinidazole 
The solid dispersion of tinidazole was prepared by kneading method 
by using methanol as a solvent [17, 18]. The mixture of tinidazole 
and PVP was wetted with methanol and kneaded thoroughly in a 
glass mortar for 20 min. The resulted homogenous mixture was 
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dried at 40˚C in a hot air oven for 24 h. The formulated powder was 
sieved through 60 mesh sieve and stored in a vacuum desiccator.  
Preparation of tinidazole raft forming tablets 
Six different raft forming tablets were prepared by varying the 
concentrations of polymers. All the ingredients, in which the 
polymers sodium alginate, HPMC, anhydrous lactose, sodium 
bicarbonate, tartaric acid and were weighed individually and shifted 
manually through mesh # 40 separately. Thereafter, tinidazole, 
sodium bicarbonates, lactose and PVP were mixed separately for 5 
min. Talc and magnesium stearate were finally added as a lubricant 
and then mixed for further 5 min. The weight of the tablet was 
determined as 500 mg and the tablets were compressed using a 
punch and die set to produce round shaped tablets [19]. 
 
Table 1: Formulation of tinidazole raft forming tablets 
Ingredients (mg) F1 F2 F3 F4 F5 F6 
Drug (tinidazole) or solid dispersed tinidazole equivalent to  100 100 100 100 100 100 
Sodium alginate  140 140 160 180 190 200 
HPMC  140 100 80 60 50 40 
PVP  - 100 100 100 100 100 
Sodium bicarbonate  20 20 20 20 20 20 
Lactose  40 - - - - - 
Tartaric acid  20 20 20 20 20 20 
Talc  10 10 10 10 10 10 
Magnesium stearate  10 10 10 10 10 10 
 
Evaluation of pre-compression parameters for powder blend 
All the pre-compression parameters like bulk density, tapped 
density, angle of repose, Carr’s index, Hausner’s ratio were 
measured according to standard procedure [20]. 
Evaluation of post-compression parameters of tinidazole raft 
forming tablets 
Tablet thickness 
The thickness of the prepared tinidazole tablets was measured by 
using Vernier calliper (Acculab, Ambala, India) in mm. Five tablets 
from each formulation were selected randomly and used for thickness 
test. 
Hardness test 
Hardness test was carried out by using “Monsanto” hardness tester 
with randomly selected five tablets by fitting them sufficiently 
between the spindle and the anvil through their diameter. Then the 
pressure on the tablet is increased by turning the knurled knob until 
the tablet breaks. The force (in Kg) required to break the tablet is 
noted from the scale. 
Friability test 
The friability of the prepared tablets was measured by “Roche” 
friabilator. 10 tablets were weighted and placed in the plastic 
chamber of friabilator and set for 25 rpm for about 4 min and the 
tablets were removed, de-dusted and reweighed. The percentage of 
friability was calculated as per formula [21]. 
% 	 =
 ℎ −  ℎ
 ℎ
× 100 
Weight variation test 
Twenty tablets were selected at random, and the average weight 
was determined. Not more than two of the individual tablets weights 
should deviate from the average weight by more than 7.5 % 
deviation and none should deviate by more than twice the 
percentage. 
Disintegration test 
Disintegration test for the prepared tinidazole raft forming tablets 
was performed in a tablet disintegration test apparatus (Electronics 
India 901, India) in simulated gastric fluid at 37+0.5 °C.  
Drug content uniformity 
10 randomly selected tablets were weighed and powdered by using 
a glass mortar and pestle [22]. A powder quantity equivalent to 50 
mg was taken and dissolved in 100 ml of 0.1 N HCl buffer. From the 
above solution, 1 ml was taken out and diluted with 9 ml of 0.1 N HCl 
buffer. Then the solution was filtered with the help of a Whatman 
filter paper. The absorbance of the filtered solution was measured 
by using a UV-VIS spectrophotometer (Elico Lab, SL 210) at λmax 286 
nm and the drug content was calculated by the following equation- 
%  
=
    ℎ 	  
ℎ       
× 100 
Floating lag time 
Floating lag time or buoyancy test was carried out in a 100 ml 
beaker containing 0.1 N HCl buffer pH 1.2. The tinidazole raft 
forming tablets were placed in the beaker and the time required to 
rise to the surface was determined as floating lag time [23].  
Raft strength measurement by in-house method 
Raft strength for the prepared tinidazole tablets was determined by 
modified physical balance method. Raft-forming tablets were placed 
into 250 ml beakers containing 150 ml of 0.1 N HCl buffer 
maintained at 37.4±0.5 ˚C. An L-shaped stainless steel wire probe 
(length = 9 cm, diameter 1.2 mm) was partially dipped into each 
beaker. The wire probe was held firmly during the period of raft 
formulation (30 min) allowing the raft to form around it. After 
completion of raft formulation, the wire probe was connected with 
one arm of a double pan dispensing balance. Water was added 
dropwise to the pan and the weight of water required to break the 
raft was recorded [24].  
Raft volume and raft weight determination 
Raft-forming tablet was placed inside a pre-weighed (W1 g) glass 
beaker containing 150 ml HCl buffer just like the above procedure 
but without any wire. The beaker was kept undisturbed for 30 min 
for completion of raft formation. When the raft formation was 
completed, the position up to which the top of each raft has reached 
was marked from outside. After raft development, the total weight of 
the beaker was measured again (W2 g). Then the raft was carefully 
separated and kept in a plastic pre-tared weighing boat. The raft was 
allowed to stand for 1 min and any trace of subnatant liquid was 
carefully taken out. The weight of the raft was measured accurately 
(W3 g). Any trace of water was wiped off from the beaker and it was 
refilled with water up to the previous mark and weighed (W4 g) [24]. 
The raft volume was calculated from the following formula by 
assuming that the density of subnatant liquid is similar to water- 
! " = #$4 − $1% − #$2 − $1 − $3% 
In vitro drug release studies 
The release of drug from different batches for the prepared tinidazole 
raft forming tablets was studied by using USP type II paddle type 
dissolution apparatus (Lab India DS 8000). The dissolution medium 
used was 900 ml of 0.1 N HCl buffer. The temperature was maintained 
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at 37 °C±0.5 °C with continuous stirring at a rate of 50 rpm. 5 ml 
samples were withdrawn at regular time intervals and the same 
volume was replaced with fresh dissolution medium to maintain the 
sink condition. The absorbance was measured by UV-VIS 
spectrophotometer (ELICO SL 210) at 286 nm. Dissolution studies 
were performed for a period of 8 h for all the formulations, and the 
cumulative percentage release of drug was calculated [25]. 
Release kinetics 
In order to understand the mechanism and kinetics of drug release, 
the result of the in vitro dissolution study of formulated particle 
were fitted with various kinetic equations, such as zero-order, first-
order, Higuchi’s model, Korsmeyer-Peppas model and Hixon-Crowell 
model [26]. Correlation coefficient (R2) values were calculated for 
the linear curves obtained by regression analysis of the above plots. 
Zero order kinetics 
The zero order describes the systems where the drug release rate is 
independent of its concentration. 
A zero order release would be predicted by the following equation,  
Q' − Q( = K(t 
Where, 
Qt = Amount of drug release dissolved in time ‘t’. 
Qo = Initial amount of drug concentration in solution. 
K0 = Zero order rate constant. 
When the data was plotted as cumulative % drug release Vs time, if 
the plot is linear then data obeys zero order kinetics with slope 
equal to K0. This model represents an ideal release profile in order to 
achieve the prolonged pharmacological action [26]. 
First order kinetics 
The first order describes the release from a system where release 
rate is concentration dependent. 
A first order release would be predicted by the following equation 
Log Q' = Log Q( −
K.t
2.303
 
Where,  
Qt = Amount of drug released at time ‘t’. 
Qo = Initial amount of drug concentration in solution.  
K1t = First order rate constant 
When data was plotted as log cumulative % drug remaining Vs time 
yields a straight line indicating that the release follows first order 
kinetics. The constant K can be obtained multiplying slope values [26]. 
Higuchi’s model 
Higuchi (1963) described the release of drugs from the insoluble matrix 
as a square root of time dependent process based on Fickian diffusion 
[26]. The graph was plotted as % cumulative drug released Vs square 
root of time. 
Q =  Kt (.3 
Where, 
K = Constant reflecting design variable system 
t = time in h 
Korsmeyer-peppas 
Korsmeyer et al. (1983) derived a simple relationship which 
described drug release from a polymeric system. To find out the 
mechanism of drug release, first, 60% drug release data was fitted in 
Korsmeyer-Peppas model. 
To evaluate the mechanism of drug release, it was further plotted in 
Peppas equation as log cumulative % of drug released Vs time.  
M'/Mα  =  Kt
6 
Log M'/Mα  =  log K + n log t  
Where,  
Mt/Mα = fraction of drug released at time t  
t = Release time  
K = Kinetic constant  
n = Diffusional exponent indicative of the mechanism drug.  
This model is used to analyse the release of pharmaceutical 
polymeric dosage forms depending on ‘n’ value when the release 
mechanism is not known or more than one type of release 
phenomenon was involved. n ≤ 0.43 symbolise Fickian release, 
0.43<n<0.85 symbolise non-Fickian release and n ≥ 0.85 indicates a 
case II transport [26]. 
Hixson-Crowell model 
The Hixson-Crowell model describes the release from systems 
where there is a change in surface area and diameter of particles or 
tablets [26]. 
Q'
./:
− Q'
./:
= K;<t 
Where,  
Qt = Remaining amount of drug in the dosage form at time t, 
Q0 = Initial amount of the drug in the tablet  
KHC = Rate constant for Hixson-Crowell rate equation  
RESULTS AND DISCUSSION 
Fourier transform infra-red spectroscopy (FT-IR) 
FTIR spectrum of tinidazole, solid dispersion of tinidazole, sodium 
alginate, HPMC, PVP and formulation were shown in fig. 1. FTIR 
spectrum of tinidazole shows a peak at 3290.81 cm-1 for aromatic C-
H stretching which can be observed in the formulation (3286.81 cm-
1) and solid dispersion of drug (3283.08 cm-1). Peaks for C-H 
stretching for alkane shows a peak at 3030.34 cm-1which is observed 
in the formulation (3103.83 cm-1) and solid dispersion (3147.87 cm-
1). N-O Symmetric stretching for nitro compound shows a peak at 
1296.82 cm-1which is observed in the formulation (1364.77 cm-1) 
and solid dispersion (1293.49 cm-1). =C-H bending for alkene shows 
a peak at 688.80 cm-1which can be observed in the formulation 
(689.53 cm-1) and solid dispersion (755.70 cm-1). C-C stretching for 
the aromatic compound is observed at 1448.76 cm-1 which can be 
seen in the formulation (1532.75 cm-1) and solid dispersion 
(1452.66 cm-1). The characteristic peaks appeared in the FT-IR 
spectrum of tinidazole is observed without any significant shifting of 
peaks, indicating the absence of any chemical interaction during and 
after preparation. 
Table 2: Post-compression parameters for tinidazole raft forming tablets 
Formulation code Thickness* (mm)±SD  Weight variation test** (%)±SD  Hardness* (Kg/cm3)±SD  Friability* (%)±SD  
F1 3.3±0.089 498±0.08 5.85±0.23 0.53±0.08 
F2 3.3±0.043 497±1.13 5.74±0.46 0.49±0.02 
F3 3.2±0.067 496±2.03 5.66±0.66 0.46±0.07 
F4 3.2±0.022 495±1.16 5.78±0.55 0.52±0.06 
F5 3.2±0.039 495±2.12 5.6±0.62 0.48±0.07 
F6 3.3±0.088 498±1.04 5.53±0.88 0.45±0.08 
*n = 10;** n=20; SD-Standard deviation 
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Fig. 1: FTIR spectrum of tinidazole, sodium alginate, HPMC K15M, PVP, solid dispersion of tinidazole and formulation 
 
Disintegration test 
Disintegration time for all the formulations was determined, and 
the values were within the range from 10±2 min to 18±3 min 
(data shown in table 3).  
Highest disintegration time was observed for F1 (18±3 min) 
which may be due to the higher concentration of HPMC acting as 
a matrix forming agent. A faster disintegration of tablets has 
been observed with decrease in HPMC concentration. 
Drug content 
The average drug content for each formulation was calculated from the 
absorbance values. The drug content for the prepared raft forming 
tablets were found within the range of 98.78±0.57 to 99.63±0.35 (as 
shown in table no 3). 
Floating lag time 
Floating lag time for all the formulations was determined in 0.1N Hcl 
buffer, and the values were within the range from 40±4 to 60±5 s (data 
shown in table 3). 
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Table 3: Various evaluation parameters for tinidazole raft forming tablets 
Formulation 
code 
% drug content* 
mean±SD 
Floating lag time* 
(s) mean±SD 
Disintegration time** 
(min) mean±SD 
Raft strength* 
mean±SD 
Raft weight* 
(g) mean±SD 
Raft volume* 
(ml) mean±SD 
F1 98.78±0.57 60±5 18±3 3.03±0.12 5.21±1.17 7.37±1.86 
F2 99.08±0.39 40±4 16±2 3.66±0.16 5.73±1.64 7.82±2.13 
F3 99.46±0.42 44±8 14±3 3.10±0.14 5.62±1.38 7.71±1.97 
F4 98.81±0.68 50±3 14±2 3.95±0.07 6.57±1.87 8.63±2.49 
F5 99.24±0.51 45±6 11±2 5.50±0.11 7.49±1.36 9.32±1.84 
F6 99.63±0.35 52±4 10±3 5.92±0.06 7.88±1.95 9.84±2.76 
*n = 3;** n=6; SD-Standard deviation 
 
Raft strength 
Raft strength for all the formulations was within the range from 
3.03±0.12 g to 5.92±0.06 g (data shown in table 3). Among all the 
formulation, F6 is having maximum raft strength which is achieved 
by more concentration of sodium alginate. The result clearly 
indicates that higher concentration of sodium alginate enhances the 
raft strength of the formulation [24]. 
Raft volume and raft weight 
The raft volume for all the formulation was found within the range 
of 7.37±1.86 ml to 9.84±2.76 ml (data provided in table 3). F1 is 
observed to have the lowest raft volume (7.37±1.86 ml), whereas F6 
produced maximum raft volume (9.84±2.76 ml). A gradual increase 
in raft volume is observed with increase in s sodium alginate 
concentration in the formulation which is due to the raft forming 
capacity of sodium alginate. Similar results were found by Dettmar 
PW et al. for alginate rafts [24]. 
Raft weight was measured after completion of raft formation for 
each formulation and was found in the range of 5.21±1.17 to 
7.88±1.95 g. F1 was found to have lowest raft weight among all 
the formulation and whereas F6 resulted in maximum raft 
weight. The variation in raft weight was directly proportional to 
the amount of sodium alginate used in the formulation [24]. 
In vitro drug release study 
In vitro dissolution of tinidazole, raft forming tablets were 
carried out in 0.1 N HCl buffer solution under sink condition up 
to 8h. F1 and F2 shown a slow release initially, whereas F3, F4, 
F5, F6 has shown an initial burst release (data shown in table 4). 
This phenomenon is observed due to the presence of solid 
dispersed tinidazole in F3-F6 formulation. The cumulative 
release of drug was found to vary between 79.71±2.18 to 
94.32±1.79 %. From the above result, it can be clearly said that 
the decrease in HPMC concentration is having a positive impact 
in drug release (fig. 2) due to variation in matrix strength of 
tablet formulation. 
In vitro release kinetics 
The release kinetics of various formulations is described in table 5. 
The time to time cumulative percentage release of tinidazole was 
fitted into different release models: Zero order, First order, Higuchi’s 
plot, Korsmeyer-Peppas and Hixson-Crowell model. The correlation 
coefficients for all the formulations were calculated from respective 
graphs. Based on the R2values, the release mechanism for F1, F2, F5 
and F6 were found to follow Korsmeyer-Peppas kinetics for which 
“n” value was found within the range of 0.27–0.69, indicating an 
anomalous release (non-Fickian kinetics corresponding to coupled 
diffusion/polymer relaxation). F3 and F4 followed Hixson-Crowell 
release kinetics. 
 
 
Fig. 2: Comparative C. P. R. of tinidazole from raft forming 
tablets 
  
Table 4: In vitro drug release for all the formulations of tinidazole raft forming tablets 
Time (h) F1  
C. P. R.±SD  
F2 
C. P. R.±SD  
F3 
C. P. R.±SD 
F4 
C. P. R.±SD  
F5 
C. P. R.±SD  
F6 
C. P. R.±SD  
0.25 8.35±0.99 7.66±0.81 28.30±0.73 30.04±0.92 31.45±0.95 23.39±0.84 
0.5 12.17±0.74 11.32±0.80 42.31±0.59 45.25±0.57 36.97±0.87 30.37±0.89 
0.75 17.74±0.96 25.01±0.61 46.32±0.85 49.47±0.80 48.92±0.60 36.31±0.83 
1 20.94±2.02 27.80±1.70 48.78±1.18 52.81±1.07 54.34±1.15 47.46±1.80 
1.5 28.23±1.38 28.47±1.12 52.72±1.47 56.73±1.13 61.65±2.69 53.61±1.21 
2 43.32±1.93 33.65±1.24 55.59±1.10 59.67±1.20 63.7±1.08 58.31±1.14 
3 56.32±2.20 40.37±2.09 57.26±1.12 61.57±1.18 66.57±1.58 62.33±2.73  
4 65.43±1.85 53.89±1.00 66.53±1.49 68.47±1.92 73.88±1.01 65.62±2.41 
5 71.63±1.90 78.02±1.51 77.66±2.30 73.51±2.06 76.70±1.06 73.32±1.03 
6 74.12±2.42 83.45±1.67 84.54±2.62 85.20±1.05 87.79±1.05 85.54±1.10 
7 76.45±1.81 84.74±1.16 87.57±1.64 88.41±2.41 88.39±2.42 89.49±1.11 
8 79.71±2.18 85.94±2.19 90.27±1.33 91.22±1.96 91.59±1.80 94.32±1.79 
n = 3; CPR-Cumulative percentage release; SD-Standard deviation 
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Table 5: Results for curve fitting of in vitro release of tinidazole from prepared tablets 
Formulation 
code 
Zero order R2 First order R2 Higuchi  
R2 
Korsmeyer-peppers Hixson-crowell 
R2 
Best fit model 
R2 N 
F1 0.7785 0.9698 0.9701 0.9796 0.6984 0.9512 Korsmeyer-Peppas 
F2 0.8685 0.9518 0.9554 0.9609 0.6908 0.9566 Korsmeyer-Peppas 
F3 0.9440 0.9712 0.8916 0.9588 0.3009 0.9757 Hixson-Crowell 
F4 0.9260 0.9554 0.9591 0.9528 0.2767 0.9632 Hixson-Crowell 
F5 0.8860 0.9686 0.958 0.9705 0.2987 0.9608 Korsmeyer-Peppas 
F6 0.0562 0.9481 0.9737 0.9782 0.3869 0.9691 Korsmeyer-Peppas 
 
CONCLUSION 
Raft-forming tablets of tinidazole were prepared with and without 
solid dispersion of drug with PVP. The floating lag time was found 
within the range of 40±4 to 60±5 s. The formation of alginate raft 
was clearly observed for all the formulation, and the raft strength 
was found satisfactory. The raft volume and raft weight was 
measured and found to increase with sodium alginate concentration. 
The in vitro drug release concluded that after 8 h of dissolution, the 
maximum release was observed for F6. It can be evidently said that 
in raft forming tablets, the dissolution rate for solid dispersed 
tinidazole has increased effectively. Controlled release of tinidazole 
is obtained by using a combination of a solid dispersion of drug with 
PVP and HPMC as a matrix forming agent. The combination of these 
two resulted in an initial increase in dissolution rate and then a 
controlled release over 8 h of time which can facilitate complete 
absorption of the drug. It can be concluded that the development of a 
raft-forming system with a solid dispersion of drug is expected to 
have a positive impact in bioavailability improvement of stomach-
specific poorly water soluble drug. 
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